Rahul Aggarwal, MD
HS Assoc Clinical Professor
Hematology and Oncology UCSF Health
I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer. I serve as the Co-Leader for the GU Medical Oncology program at UCSF.
My research focus is on developing novel therapies and imaging modalities for patients with advanced solid tumor malignancies, with a focus on patients with advanced prostate cancer.
Education
Fellowship, 2013 - Hematology/Oncology, University of California, San Francisco
Residency, 2009 - School of Medicine - Internal Medicine, University of California, San Francisco
M.D., 2006 - School of Medicine, Northwestern University Feinberg
Honors and Awards
- Department of Defense Prostate Cancer Program Idea Development Award, 2016-2019
- Cancer Clinical Investigator Team Leadership Award, National Cancer Institute, 2016-2017
- Department of Defense Prostate Cancer Program Physician Research Training Award, 2016
- Prostate Cancer Foundation Young Investigator Award, 2015-2017
- Alliance Cooperative Group Scholar Award, 2013
- ASCO Young Investigator Award, 2012-2013
- Pfizer Fellowship in Oncology, 2011-2012
Publications
- Autoantibody landscape in patients with advanced prostate cancer.
- The synthesis and structural requirements for measuring glucocorticoid receptor expression in vivo with (±)-11C-YJH08 PET.
- Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.
- Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
- A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer.
- The DNA methylation landscape of advanced prostate cancer.
- Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
- Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
- Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer.
- A novel radioligand reveals tissue specific pharmacological modulation of glucocorticoid receptor expression with positron emission tomography.
- Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
- Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm.
- Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
- Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.
- Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.
- Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study.
- Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
- Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
- Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
- MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
- Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies.
- Reply to A. Dalla Volta et al.
- First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer.
- Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients.
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
- Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
- Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients.
- Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
- Spatio-Temporally Constrained Reconstruction for Hyperpolarized Carbon-13 MRI Using Kinetic Models.
- Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
- Technique development of 3D dynamic CS-EPSI for hyperpolarized 13 C pyruvate MR molecular imaging of human prostate cancer.
- A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.
- Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer.
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
- Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
- Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer.
- A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
- Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
- Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
- Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
- Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.
- Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications.
- Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.
- High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
- CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.
- Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
- Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer.
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
- A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
- Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.
- A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer.
- Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.
- 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
- Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
- Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure?
- Approaches to minimize castration in the treatment of advanced prostate cancer.
- A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
- First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
- Somatostatin imaging of neuroendocrine-differentiated prostate cancer.
- Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With
- Small-cell/neuroendocrine prostate cancer: a growing threat?
- Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.
- Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
- Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
- The changing role of imaging in clinical care.
- The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
- Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
- Castration-resistant prostate cancer: targeted therapies and individualized treatment.
- The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.